NOVABIO Research Profile

What Is Kisspeptin-10 (KP-10)?

Kisspeptin-10 (KP-10) is a short peptide fragment identified by the established Kisspeptin-10 designation. This page identifies the material as Kisspeptin-10 (KP-10), with amino acid count 10; synonyms Metastin(45-54); KP-10. The Kisspeptin-10 (KP-10) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Exact-product regulatory reviewLast verified 2026-10-06
Catalogue identityKisspeptin-10 (KP-10)
Available specifications5mg, 10mg
Evidence snapshot5 trials · 405 publications
Last verified2026-10-06

What Is Kisspeptin-10 (KP-10)?

Kisspeptin-10 (KP-10) is a short peptide fragment identified by the established Kisspeptin-10 designation. This page identifies the material as Kisspeptin-10 (KP-10), with amino acid count 10; synonyms Metastin(45-54); KP-10. The Kisspeptin-10 (KP-10) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

5ClinicalTrials.gov query records
405PubMed query records
6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Kisspeptin-10 (KP-10) is organized around kisspeptin receptor research, endocrine-signaling literature, short-peptide characterization, and analytical peptide workflows. For Kisspeptin-10 (KP-10), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / StudyPhaseStatusContextLast registry update
NCT03771326KP-10 and Insulin Secretion in MenPhase 3CompletedKisspeptin Action on Insulin in Healthy Normal Men, Kisspeptin Action on Insulin in Obese Diabetic Men2018-12-12
NCT04532801Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal TolerancePhase 1WithdrawnInsulin, Glucose, Healthy Volunteers, Women, Pregnancy2024-08-01
NCT05456854Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic ClampPhase 1WithdrawnMetabolic Disease2024-08-14
NCT03286517Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.Phase 3CompletedReproductive Physiological Phenomena2017-09-18
NCT03315325Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in MenPhase 3CompletedSterility, Reproductive2017-10-23

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2017 Aug

PMID 28393578
Selected PubMed record

Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry.

Biomedical chromatography : BMC · 2024 Sep

PMID 38978171
Selected PubMed record

Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src.

Nature communications · 2024 Feb 12

PMID 38346942
Selected PubMed record

Kisspeptin (Kp-10) inhibits in vitro osteogenic differentiation of multipotent mesenchymal stromal cells extracted from the bone marrow of adult rats.

Acta histochemica · 2023 Dec

PMID 37948785
Selected PubMed record

Kisspeptin-10 (KP-10) stimulates osteoblast differentiation through GPR54-mediated regulation of BMP2 expression and activation.

Scientific reports · 2018 Feb 1

PMID 29391507
Selected PubMed record

Author Correction: Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src.

Nature communications · 2024 Dec 19

PMID 39702286

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend
Kisspeptin-10 (KP-10)
Available Specifications
5mg, 10mg
Pack Format
10 Vials
CAS Number
374675-21-5
Molecular Formula
C63H83N17O14
Molecular Weight
1302.47 g/mol
Amino Acid Count
10
Sequence
H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Synonyms
Metastin(45-54); KP-10
Physical Form
Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 25240297 · Product form must still be matched to the catalogue and batch record.

Research Tools for Kisspeptin-10 (KP-10)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA
Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Kisspeptin-10 (KP-10) Research Summary

Identity

Kisspeptin-10 (KP-10); specifications: 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

The research record for Kisspeptin-10 (KP-10) is organized around kisspeptin receptor research, endocrine-signaling literature, short-peptide characterization, and analytical peptide workflows. For Kisspeptin-10 (KP-10), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Evidence

5 registry records and 405 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Kisspeptin-10 (KP-10) is represented here by the catalogue identity Kisspeptin-10 (KP-10). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Kisspeptin-10 (KP-10) is organized around kisspeptin receptor research, endocrine-signaling literature, short-peptide characterization, and analytical peptide workflows. For Kisspeptin-10 (KP-10), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 5 ClinicalTrials.gov records and 405 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Kisspeptin-10 (KP-10) FAQ

What is Kisspeptin-10 (KP-10)?

Kisspeptin-10 (KP-10) is a short peptide fragment identified by the established Kisspeptin-10 designation. This page identifies the material as Kisspeptin-10 (KP-10), with amino acid count 10; synonyms Metastin(45-54); KP-10. The Kisspeptin-10 (KP-10) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

What research records are indexed for Kisspeptin-10 (KP-10)?

The synchronized query returned 5 ClinicalTrials.gov records and 405 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Kisspeptin-10 (KP-10) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources
ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved
2026-10-06T12:08:49Z
Inclusion
Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations
Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by
NOVABIO Research
Reviewed date
2026-10-06
Editorial methodology
How NOVABIO builds Research Profiles
Corrections contact
Contact NOVABIO with the page URL and source record.